This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-growth: Archive
Is It Worth Investing in Deckers (DECK) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Deckers (DECK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
DECKPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Adobe (ADBE) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Adobe (ADBE) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
ADBENegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts Think Accenture (ACN) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Accenture (ACN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ACNPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Workday (WDAY): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Workday (WDAY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
WDAYPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in Lithium Americas Corp. (LAC) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Lithium Americas Corp. (LAC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
LACPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts Think SkyWest (SKYW) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for SkyWest (SKYW) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
SKYWPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts Think Comcast (CMCSA) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Comcast (CMCSA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
CMCSAPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
3 Reasons Growth Investors Will Love Willdan (WLDN)
by Zacks Equity Research
Willdan (WLDN) could produce exceptional returns because of its solid growth attributes.
WLDNPositive Net Change
earnings-growth growth-investing growth-investors growth-stocks
Is TransDigm (TDG) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
TransDigm (TDG) possesses solid growth attributes, which could help it handily outperform the market.
TDGPositive Net Change
earnings-growth growth-investing growth-investors growth-stocks
Badger Meter (BMI) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Badger Meter (BMI) possesses solid growth attributes, which could help it handily outperform the market.
BMINegative Net Change
earnings-growth growth-investing growth-investors growth-stocks
Is P&G (PG) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in P&G (PG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
PGNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in ON Semiconductor Corp. (ON): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for ON Semiconductor Corp. (ON) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
ONPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in Monday.com (MNDY) Based on Wall Street's Bullish Views?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Monday.com (MNDY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
MNDYPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Tenet (THC) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Tenet (THC) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
THCNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in AbbVie (ABBV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
ABBVNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in High Tide (HITI) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in High Tide (HITI). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
HITINegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Nu (NU) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Nu (NU) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
NUPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
DraftKings (DKNG) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), DraftKings (DKNG) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
DKNGNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts Think MasterCard (MA) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in MasterCard (MA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
MANegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Brokers Suggest Investing in Lockheed (LMT): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Lockheed (LMT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
LMTNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Crocs (CROX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Crocs (CROX) possesses solid growth attributes, which could help it handily outperform the market.
CROXPositive Net Change
earnings-growth growth-investing growth-investors growth-stocks
Brokers Suggest Investing in KLA (KLAC): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in KLA (KLAC). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
KLACPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts Think CleanSpark (CLSK) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in CleanSpark (CLSK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
CLSKPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Should You Invest in British American Tobacco (BTI) Based on Bullish Wall Street Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in British American Tobacco (BTI). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
BTIPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
VKTXNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth